<DOC>
	<DOCNO>NCT01822808</DOCNO>
	<brief_summary>To investigate effect hydralazine isosorbide dinitrate clinical outcome , symptom , cardiac parameter functional status African patient hospitalize AHF leave ventricular dysfunction 24 week therapy . Administration hydralazine/nitrates superior placebo administration reduce HF readmission death , improve dyspnoea , reduce blood pressure brain natriuretic peptide ( BNP ) African patient admit AHF leave ventricular dysfunction .</brief_summary>
	<brief_title>Bi Treatment With Hydralazine/Nitrates Versus Placebo Africans Admitted With Acute Heart Failure</brief_title>
	<detailed_description>Heart failure ( HF ) pathophysiologic condition final common pathway form cardiovascular disease . Patients HF experience poor quality life , recurrent emergency hospitalization premature mortality . Recent publication highlight multiple challenge deal increase burden heart disease within urban African community . The predominance woman novel underlying cause contrast demographic HF high income country . More 50 % 5328 de novo case heart disease capture tertiary clinic Soweto present form heart failure , mainly due poorly treat hypertension , idiopathic dilate cardiomyopathy , peripartum cardiomyopathy HIV-related cardiomyopathy . The prevalent form heart disease hypertensive heart failure ( &gt; 1100 case ) . Programs develop high income country cost-effectively prevent progressive cardiac dysfunction high risk individual apply evidence-based treatment optimize overall management HF . There , however , paucity data describe etiology underlying cardiac structure function , well contemporary management HF low middle income country . In 2005 number lead clinician Africa US publish `` call action '' highlight need African study document aetiology acute heart failure management practice apply patient . As result , The Sub-Saharan Africa Survey Heart Failure ( THESUS HF ) study , initiate 9 country Africa determine aetiology , treatment , morbidity mortality acute heart failure ( HF ) African sub-continent . The data report study unique first large outcome study acute heart failure continent . This first multinational study 1000 patient acute decompensated heart failure conduct region sub-Saharan Africa show , first time , treatment heart failure sub-optimal region , relatively low proven medical treatment ( beta-blockers , hydralazine nitrate ) inappropriately high use aspirin cohort patient non-ischaemic heart failure . This study also clear purpose enhance research capacity Africa via collaborative research outline publication . The use Ace inhibitor ( ACEi ) hydralazine/nitrates never examine patient admit acute heart failure . All study demonstrate beneficial effect drug perform patient chronic heart failure . Previous study show administration ACEi African Americans chronic heart failure less effective superior combine treatment hydralazine/isosorbide dinitrate . The African American Heart Failure Trial ( A-HeFT ) establish benefit adjunctive administration isosorbide dinitrate/hydralazine ( ISDN/HYD ) addition standard therapy African American patient symptomatic heart failure . The risk death reduce 33 % marker quality life improve . The THESUS registry show high prevalence hypertension leave ventricular systolic dysfunction ( hypertensive heart failure ) dilate cardiomyopathy cause acute heart failure participate African country . Patients Africa rarely treat combination therapy fix combination ( Bidil ) unavailable Africa . There uncertainty combination hydralazine isosorbide dinitrate , available generic agent , beneficial Africans many physician Africa aware outcome study publish high impact factor journal , often available local doctor . Performing multicentre study Africa could confirm data obtain African Americans , create awareness promising combination treatment extend use medication patient acute heart failure . This BAHEF protocol approve 'Amendment # 1 ' date 29 April 2013 . Amendments change Eligibility criterion change site . To date , 22 Sept 2014 , BAHEF study enrol 110 study subject . To date , 13 Aug 2015 , BAHEF study enrol 145 eligible subject .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Ventricular Dysfunction</mesh_term>
	<mesh_term>Ventricular Dysfunction , Left</mesh_term>
	<mesh_term>Isosorbide-5-mononitrate</mesh_term>
	<mesh_term>Isosorbide Dinitrate</mesh_term>
	<mesh_term>Hydralazine</mesh_term>
	<mesh_term>Isosorbide</mesh_term>
	<criteria>1 . &gt; 18 year age 2 . Hospital admission acute heart failure define presence acute dyspnea presence clinical sign heart failure physical examination . 3 . Where available , NTproBNP &gt; 900 pg/ml , &gt; 1800 pg/ml patient atrial fibrillation screen &gt; 450 pg/ml BMI &gt; 35 kg/m2 , LVEF &lt; 45 % assessed echocardiography method within previous 12 month 4 . Background therapy least ACEinhibitor angiotensin receptor blocker ( ARB ) betablocker ( unless betablocker contraindicate due severe volume overload , low output heart failure , cardiogenic shock ) 5 . Available regular follow 1 . Currently treat Hydralazine and/or nitrate history intolerance oral therapy either hydralazine nitrate . 2. . Any intravenous treatment heart failure , except IV furosemide ( eg . IV inotropes , pressor , nitrate nesiritide ) time screen . 3 . Systolic blood pressure &lt; 100 mmHg 4 . Plan revascularization 5 . Greater 96 hour admission 6 . Reversible etiology acute heart failure myocarditis , acute myocardial infarction , arrhythmia . Acute MI define symptom major electrocardiogram ( ECG ) change ( i.e. , ST segment elevation ) , arrhythmia include unstable heart rate 120/min 50/min . 7 . Hypertrophic obstructive cardiomyopathy , constrictive cardiomyopathy , endomyocardial fibroelastosis 8 . Known severe congenital heart disease ( uncorrected tetralogy fallot transposition aorta ) 9 . Severe aortic mitral stenosis severe rheumatic mitral regurgitation . 10 . Renal impairment ( defined creatinine &gt; 3 mg/dL ) screen type dialysis . 11 . Known hepatic impairment ( total bilirubin &gt; 3mg/dl ) increase ammonia level screen . 12 . History systemic lupus erythematous . 13 . Stroke TIA within 2 week screen . 14 . Women pregnant lactating . 15 . Allergy organic nitrate . 16 . History presence disease ( ie . Including malignancy AIDS ) life expectancy &lt; 12 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>acute heart failure</keyword>
	<keyword>leave ventricular dysfunction</keyword>
	<keyword>hydralazine</keyword>
	<keyword>isosorbide dinitrate</keyword>
</DOC>